Aug 04, 2023 13:04 JST

Source: Eisai

Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment

TOKYO, Aug 04, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global environmental, social and governance (ESG) standards. Eisai received particularly high scores in "Corporate Governance", "Anti-Corruption", "Tax Transparency", "Labor Standards" and "Customer Responsibility", among others. As of the end of June 2023, 1,121 companies worldwide and 250 Japanese companies were included in the FTSE4Good Developed Index Series.

Currently, in addition to the MSCI ESG Leaders Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN) and the S&P/JPX Carbon Efficient Index, which are ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate concept is to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides to them, as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this concept.

For more information on our ESG initiatives, please visit www.eisai.com/sustainability/index.html.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
November 30 2023 15:25 JST
 
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
November 22 2023 08:28 JST
 
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
November 20 2023 16:05 JST
 
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
October 25 2023 19:43 JST
 
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
October 16 2023 13:07 JST
 
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
October 11 2023 12:07 JST
 
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
October 04 2023 18:08 JST
 
Eisai Launches New "Innovation" Page on Corporate Website
September 28 2023 16:05 JST
 
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
September 28 2023 13:49 JST
 
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
September 25 2023 14:17 JST
 
More Press release >>

Latest Press Release


More Latest Release >>